- In October 2023, the FDA granted approval for Cabtreo, a topical gel comprising clindamycin phosphate, adapalene, and benzoyl peroxide, to treat acne vulgaris in patients aged 12 and above. Clindamycin phosphate is an antibiotic that reduces acne-causing bacteria, adapalene is a retinoid that unclogs pores and reduces inflammation, while benzoyl peroxide works by killing bacteria and reducing excess oil production. This combination offers a comprehensive approach to treating acne, targeting multiple factors contributing to its development, and providing a promising option for patients seeking effective skincare solutions
